Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

TRITON-PN: En studie for å evaluere effektiviteten og sikkerheten til Nucresiran hos pasienter med arvelig transtyretyn-amyloidose med polynevropati (TRITON-PN)

16. november 2026 oppdatert av: Alnylam Pharmaceuticals

TRITON-PN: En fase 3, global, randomisert, åpen studie for å evaluere effektiviteten og sikkerheten til Nucresiran hos pasienter med arvelig transtyreitin-mediert amyloidose med polynevropati (hATTR-PN)

The purpose of this study is to:

  • Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed
  • Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

125

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

      • Belgrano, Argentina, C1428AQK
        • Rekruttering
        • Clinical Trial Site
      • Rosario, Argentina, CP2000
        • Rekruttering
        • Clinical Trial Site
      • Darlinghurst, Australia, 2010
        • Rekruttering
        • Clinical Trial Site
      • Woolloongabba, Australia, 4102
        • Rekruttering
        • Clinical Trial Site
      • Ribeirão Preto, Brasil, 14051-140
        • Rekruttering
        • Clinical Trial Site
      • Rio de Janeiro, Brasil, 22640-100
        • Rekruttering
        • Clinical Trial Site
      • Rio de Janeiro, Brasil, 22775-001
        • Rekruttering
        • Clinical Trial Site
      • Salvador, Brasil, 40290-000
        • Rekruttering
        • Clinical Trial Site
      • São Paulo, Brasil, 04038-002
        • Rekruttering
        • Clinical Trial Site
      • Vancouver, Canada, V5Z 1M9
        • Rekruttering
        • Clinical Trial Site
    • Colorado
      • Aurora, Colorado, Forente stater, 80045
        • Rekruttering
        • Clinical Trial Site
    • Illinois
      • Chicago, Illinois, Forente stater, 60611
        • Rekruttering
        • Clinical Trial Site
    • Maryland
      • Baltimore, Maryland, Forente stater, 21287
        • Rekruttering
        • Clinical Trial Site
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02118
        • Rekruttering
        • Clinical Trial Site
    • Minnesota
      • Rochester, Minnesota, Forente stater, 55905
        • Rekruttering
        • Clinical Trial Site
    • New York
      • New York, New York, Forente stater, 10032
        • Rekruttering
        • Clinical Trial Site
      • New York, New York, Forente stater, 10016
        • Rekruttering
        • Clinical Trial Site
    • North Carolina
      • Chapel Hill, North Carolina, Forente stater, 27514
        • Rekruttering
        • Clinical Trial Site
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37232
        • Rekruttering
        • Clinical Trial Site
    • Texas
      • Dallas, Texas, Forente stater, 75246
        • Rekruttering
        • Clinical Trial Site
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • Clinical Trial Site
      • Créteil, Frankrike, 94000
        • Rekruttering
        • Clinical Trial Site
      • Le Kremlin-Bicêtre, Frankrike, 94270
        • Rekruttering
        • Clinical Trial Site
      • Marseille, Frankrike, 13005
        • Rekruttering
        • Clinical Trial Site
      • Athens, Hellas, 115 28
        • Rekruttering
        • Clinical Trial Site
      • Heraklion, Hellas, 715 00
        • Rekruttering
        • Clinical Trial Site
      • Dublin, Irland, D24 NR0A
        • Rekruttering
        • Clinical Trial Site
      • Florence, Italia, 50134
        • Rekruttering
        • Clinical Trial Site
      • Milan, Italia, 20133
        • Rekruttering
        • Clinical Trial Site
      • Padova, Italia, 35128
        • Rekruttering
        • Clinical Trial Site
      • Pavia, Italia, 27100
        • Rekruttering
        • Clinical Trial Site
      • Roma, Italia, 00168
        • Rekruttering
        • Clinical Trial Site
      • Bunkyo C, Japan, 113-8519
        • Rekruttering
        • Clinical Trial Site
      • Kumamoto, Japan, 860-8556
        • Rekruttering
        • Clinical Trial Site
      • Matsumoto-shi, Japan, 390-8621
        • Rekruttering
        • Clinical Trial Site
      • Suita, Japan, 565-0871
        • Rekruttering
        • Clinical Trial Site
      • Égkomi, Kypros, 2371
        • Rekruttering
        • Clinical Trial Site
      • Kuala Lumpur, Malaysia, 59100
        • Rekruttering
        • Clinical Trial Site
      • Guadalajara, Mexico, 44670
        • Rekruttering
        • Clinical Trial Site
      • Tlalpan, Mexico, 14080
        • Rekruttering
        • Clinical Trial Site
      • Lisbon, Portugal, 1649-035
        • Rekruttering
        • Clinical Trial Site
      • Porto, Portugal, 4099-001
        • Rekruttering
        • Clinical Trial Site
      • Barcelona, Spania, 08035
        • Rekruttering
        • Clinical Trial Site
      • Huelva, Spania, 21005
        • Rekruttering
        • Clinical Trial Site
      • L'Hospitalet de Llobregat, Spania, 8907
        • Rekruttering
        • Clinical Trial Site
      • Madrid, Spania, 28040
        • Rekruttering
        • Clinical Trial Site
      • Palma de Mallorca, Spania, 07198
        • Rekruttering
        • Clinical Trial Site
      • London, Storbritannia, NW3 2QG
        • Rekruttering
        • Clinical Trial Site
      • Bern, Sveits, 3010
        • Rekruttering
        • Clinical Trial Site
      • Stockholm, Sverige, 113 61
        • Rekruttering
        • Clinical Trial Site
      • Umeå, Sverige, 907 37
        • Rekruttering
        • Clinical Trial Site
      • Seoul, Sør -Korea, 06351
        • Rekruttering
        • Clinical Trial Site
      • Seoul, Sør -Korea, 05030
        • Rekruttering
        • Clinical Trial Site
      • Taipei, Taiwan, 10002
        • Rekruttering
        • Clinical Trial Site
      • Taipei, Taiwan, 112
        • Rekruttering
        • Clinical Trial Site
      • Taoyuan City, Taiwan, 33305
        • Rekruttering
        • Clinical Trial Site
      • Istanbul, Tyrkia (Türkiye), 34093
        • Rekruttering
        • Clinical Trial Site
      • Izmir, Tyrkia (Türkiye), 35330
        • Rekruttering
        • Clinical Trial Site
      • Berlin, Tyskland, 10117
        • Rekruttering
        • Clinical Trial Site
      • Heidelberg, Tyskland, 69120
        • Rekruttering
        • Clinical Trial Site
      • Münster, Tyskland, 48149
        • Rekruttering
        • Clinical Trial Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 85 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Has documented diagnosis of hATTR-PN
  • Has a diagnosis of hATTR amyloidosis with polyneuropathy with a documented TTR gene variant
  • Has a neuropathy impairment score (NIS) of 5 to 130 (inclusive)
  • Has a Karnofsky Performance Status (KPS) of ≥60%

Exclusion Criteria:

  • Has had a liver transplant or is likely, in the opinion of the Investigator, to undergo liver transplantation during the Treatment Period of the study
  • Has known other (non-hATTR) forms of amyloidosis or clinical evidence of leptomeningeal amyloidosis
  • Has a New York Heart Association (NYHA) heart failure classification >2
  • Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 upper limit of normal (ULN)
  • Has total bilirubin >1.5 ULN
  • Has estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73m^2
  • Has other known causes of sensorimotor or autonomic neuropathy

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Nucresiran 300 mg

Patients will be administered nucresiran 300 mg subcutaneously (SC) once every 6 months (q6M) during the Treatment Period and Treatment Extension Period

Nucresiran 300 mg administered SC q6M

Andre navn:
  • ALN-TTRSC04
Aktiv komparator: Vutrisiran 25 mg followed by Nucresiran 300 mg

Patients will be administered vutrisiran 25 mg SC every 3 months (q3M) during the Treatment Period followed by nucresiran 300 mg SC q6M during the Treatment Extension Period

Nucresiran 300 mg administered SC q6M

Andre navn:
  • ALN-TTRSC04

Vutrisiran 25 mg administered SC q3M

Andre navn:
  • ALN-TTRSC02
  • AMVUTTRA

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change from Baseline in the Modified Neuropathy Impairment Score +7 (mNIS+7) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Tidsramme: Baseline and Month 9

The mNIS+7 is a composite score that measures neurologic impairment which includes the following components: physical exam of lower limbs, upper limbs and cranial nerves to assess motor strength/weakness and deep tendon reflexes, electrophysiologic measurement of large nerve fiber function, sensory testing and postural blood pressure. The mNIS+7 is scored from 0 (no impairment) to 304 points (maximum impairment). A higher score indicates a worse outcome.

Baseline and Month 9

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Prosentvis reduksjon i serum TTR-nivå i nukresiran-gruppen sammenlignet med vutrisiran-gruppen i studien gjennom måned 9
Tidsramme: Opp til måned 9
Opp til måned 9
Prosentvis reduksjon i serum TTR-nivåer i nukresiran-gruppen sammenlignet med vutrisiran-gruppen i studien gjennom måned 18
Tidsramme: Opptil måned 18
Opptil måned 18
Prosentvis reduksjon i serum TTR-nivåer i Nucresiran-gruppen sammenlignet med Vutrisiran-gruppen i studien ved uke 6
Tidsramme: Uke 6
Uke 6
Change from Baseline in Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) Total Score Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Tidsramme: Baseline and Month 9

The Norfolk QoL-DN is a standardized 35-item patient-rated questionnaire used to assess 5 domains: physical function, large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome.

Baseline and Month 9
Change from Baseline in Modified Body Mass Index (mBMI) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 9
Tidsramme: Baseline and Month 9

The mBMI, which is a measure of nutritional status, is calculated as the product of body mass index (BMI) (weight in kilograms divided by the square of height in meters) and serum albumin (g/L) to reflect fluid balance, such as fluid accumulation or dehydration. A negative change from baseline indicates a better outcome.

Baseline and Month 9
Change from Baseline in the mNIS+7 Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tidsramme: Baseline and Month 18

The mNIS+7 is a composite score that measures neurologic impairment which includes the following components: physical exam of lower limbs, upper limbs and cranial nerves to assess motor strength/weakness and deep tendon reflexes, electrophysiologic measurement of large nerve fiber function, sensory testing and postural blood pressure. The mNIS+7 is scored from 0 (no impairment) to 304 points (maximum impairment). A higher score indicates a worse outcome.

Baseline and Month 18
Change from Baseline in Norfolk QoL-DN Total Score Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tidsramme: Baseline and Month 18

The Norfolk QoL-DN is a standardized 35-item patient-rated questionnaire used to assess 5 domains: physical function, large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome.

Baseline and Month 18
Change from Baseline in mBMI Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tidsramme: Baseline and Month 18

The mBMI, which is a measure of nutritional status, is calculated as the product of body mass index (BMI) (weight in kilograms divided by the square of height in meters) and serum albumin (g/L) to reflect fluid balance, such as fluid accumulation or dehydration. A negative change from baseline indicates a better outcome.

Baseline and Month 18
Change from Baseline in Rasch-built Overall Disability Scale (R-ODS) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tidsramme: Baseline and Month 18

The R-ODS is a patient-reported measure of level of disability on a scale of 0-48, with 0 being the worst and 48 the best (no limitations); scores are based on activities of daily living and social participation. An increase in R-ODS from baseline suggests improvement in disability, and a decrease from baseline suggests worsening of disability.

Baseline and Month 18
Change from Baseline in Timed 10-meter Walk Test (10-MWT) Compared to the External Placebo Group from the APOLLO Study (NCT01960348) at Month 18
Tidsramme: Baseline and Month 18

The timed 10-MWT is a measure of ambulatory ability and measures the time (in seconds) that it takes a participant to walk 10 meters (gait speed). An increase in gait speed from baseline represents improvement, and a decrease from baseline represents worsening.

Baseline and Month 18

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Medical Director, Alnylam Pharmaceuticals

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

3. februar 2026

Primær fullføring (Antatt)

27. desember 2027

Studiet fullført (Antatt)

12. juni 2031

Datoer for studieregistrering

Først innsendt

29. oktober 2025

Først innsendt som oppfylte QC-kriteriene

29. oktober 2025

Først lagt ut (Faktiske)

31. oktober 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • ALN-TTRSC04-004
  • 2025-522544-40-00 (Ctis)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Phase 2-4 trials:

Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU.

Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, a planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more.

Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .